sentence
stringlengths 27
1.01k
| drug1
stringlengths 2
46
| drug2
stringlengths 2
63
| relation
stringclasses 5
values | source_file
stringclasses 566
values | sentence_id
stringlengths 17
21
| pair_id
stringlengths 20
26
|
|---|---|---|---|---|---|---|
The prior administration of succinylcholine does not enhance the duration, but quickens the onset and may increase the depth, of neuromuscular block induced by TRACRIUM.
|
succinylcholine
|
TRACRIUM
|
EFFECT
|
Atracurium_ddi.xml
|
DDI-DrugBank.d469.s9
|
DDI-DrugBank.d469.s9.p0
|
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.
|
quinolone
|
VIDEX
|
MECHANISM
|
Ciprofloxacin_ddi.xml
|
DDI-DrugBank.d123.s8
|
DDI-DrugBank.d123.s8.p5
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
ritonavir
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p4
|
Wait 2 weeks after stopping an MAO inhibitor before starting escitalopram.
|
MAO inhibitor
|
escitalopram
|
ADVISE
|
Fluoxetine_ddi.xml
|
DDI-DrugBank.d482.s10
|
DDI-DrugBank.d482.s10.p0
|
Considerable caution should be exercised if PEGANONE is administered concurrently with Phenurone (phenacemide) since paranoid symptoms have been reported during therapy with this combination.
|
PEGANONE
|
Phenurone
|
ADVISE
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s1
|
DDI-DrugBank.d359.s1.p0
|
There were transient increases in liver ALT and AST when CANCIDAS and cyclosporine were co-administered.
|
CANCIDAS
|
cyclosporine
|
EFFECT
|
Caspofungin_ddi.xml
|
DDI-DrugBank.d350.s9
|
DDI-DrugBank.d350.s9.p0
|
When other potent parental antihypertensive drugs, such as diazoxide, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.
|
antihypertensive drugs
|
hydralazine
|
EFFECT
|
Hydralazine_ddi.xml
|
DDI-DrugBank.d31.s1
|
DDI-DrugBank.d31.s1.p1
|
Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and PEGASYS.
|
theophylline
|
PEGASYS
|
ADVISE
|
Peginterferon alfa-2a_ddi.xml
|
DDI-DrugBank.d196.s1
|
DDI-DrugBank.d196.s1.p2
|
The clearance of salicylates may be increased with concurrent use of corticosteroids.
|
salicylates
|
corticosteroids
|
MECHANISM
|
Dexamethasone_ddi.xml
|
DDI-DrugBank.d314.s26
|
DDI-DrugBank.d314.s26.p0
|
Aminosalicylic acid may decrease the amount of digoxin (Lanoxin, Lanoxicaps) that gets absorbed into your body.
|
Aminosalicylic acid
|
digoxin
|
MECHANISM
|
Aminosalicylic Acid_ddi.xml
|
DDI-DrugBank.d22.s0
|
DDI-DrugBank.d22.s0.p0
|
Clofibric acid: Combination hormonal contraceptives may increase the clearance of clofibric acid.
|
hormonal contraceptives
|
clofibric acid
|
MECHANISM
|
Ethynodiol Diacetate_ddi.xml
|
DDI-DrugBank.d485.s18
|
DDI-DrugBank.d485.s18.p2
|
Digoxin: Some calcium blockers may increase the concentration of digitalis preparations in the blood.
|
calcium blockers
|
digitalis preparations
|
MECHANISM
|
Nicardipine_ddi.xml
|
DDI-DrugBank.d468.s4
|
DDI-DrugBank.d468.s4.p2
|
Caution should be taken when ENABLEX is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as flecainide, thioridazine and tricyclic antidepressants (see CLINICAL PHARMACOLOGY).
|
ENABLEX
|
thioridazine
|
ADVISE
|
Darifenacin_ddi.xml
|
DDI-DrugBank.d459.s1
|
DDI-DrugBank.d459.s1.p1
|
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium.
|
ACE inhibitors
|
lithium
|
MECHANISM
|
Benazepril_ddi.xml
|
DDI-DrugBank.d561.s7
|
DDI-DrugBank.d561.s7.p9
|
Antidepressants, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;
|
Amphetamines
|
tricyclic antidepressants
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s3
|
DDI-DrugBank.d158.s3.p7
|
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.
|
Benzthiazide
|
blood thinner
|
INT
|
Benzthiazide_ddi.xml
|
DDI-DrugBank.d208.s0
|
DDI-DrugBank.d208.s0.p1
|
Phenobarbital: Coadministration of felbamate with phenobarbital causes an increase in phenobarbital plasma concentrations, In 12 otherwise healthy male volunteers ingesting phenobarbital, the steady-state trough (Cmin) phenobarbital concentration was 14.2 micrograms/mL.
|
phenobarbital
|
phenobarbital
|
NONE
|
Felbamate_ddi.xml
|
DDI-DrugBank.d434.s28
|
DDI-DrugBank.d434.s28.p12
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
morphine
|
theophylline
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p921
|
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.
|
alprazolam
|
cyclosporine
|
INT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s10
|
DDI-DrugBank.d131.s10.p7
|
Drugs that reportedly may increase oral anticoagulant response, ie, increased prothrombin response, in man include:alcohol*;allopurinol;aminosalicylic acid;amiodarone;anabolic steroids;antibiotics;bromelains;chloral hydrate*;chlorpropamide;chymotrypsin;cimetidine;cinchophen;clofibrate;dextran;dextrothyroxine;diazoxide;dietary deficiencies;diflunisal;disulfiram;drugs affecting blood elements;ethacrynic acid;fenoprofen;glucagon;hepatotoxic drugs;ibuprofen;indomethacin;influenza virus vaccine;inhalation anesthetics;mefenamic acid;methyldopa;methylphenidate;metronidazole;miconazole;monoamine oxidase inhibitors;nalidixic acid;naproxen;oxolinic acid;oxyphenbutazone;pentoxifylline;phenylbutazone;phenyramidol;phenytoin;prolonged hot weather;prolonged narcotics;pyrazolones;quinidine;quinine;ranitidine*;salicylates;sulfinpyrazone;sulfonamides, long acting;sulindac;thyroid drugs;tolbutamide;triclofos sodium;trimethoprim/sulfamethoxazole;unreliable prothrombin time determinations;warfarin sodium overdosage.
|
aminosalicylic acid
|
chloral hydrate
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s87
|
DDI-DrugBank.d64.s87.p163
|
Concomitant administration of FACTIVE and calcium carbonate, cimetidine, omeprazole, or an estrogen/progesterone oral contraceptive produced minor changes in the pharmacokinetics of gemifloxacin, which were considered to be without clinical significance.
|
FACTIVE
|
progesterone
|
MECHANISM
|
Gemifloxacin_ddi.xml
|
DDI-DrugBank.d347.s1
|
DDI-DrugBank.d347.s1.p4
|
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.
|
phenytoin
|
clonazepam
|
NONE
|
Clonazepam_ddi.xml
|
DDI-DrugBank.d333.s5
|
DDI-DrugBank.d333.s5.p3
|
In patients receiving nonselective monoamine oxidase inhibitors (MAOIs) (e.g., selegiline hydrochloride) in combination with serotoninergic agents (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine), there have been reports of serious, sometimes fatal, reactions.
|
selegiline hydrochloride
|
serotoninergic agents
|
EFFECT
|
Dexfenfluramine_ddi.xml
|
DDI-DrugBank.d423.s0
|
DDI-DrugBank.d423.s0.p15
|
Aspirin, warfarin, heparin, NSAIDs
|
warfarin
|
heparin
|
NONE
|
Clopidogrel_ddi.xml
|
DDI-DrugBank.d343.s0
|
DDI-DrugBank.d343.s0.p3
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
sodium colistemethate
|
lithium
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p106
|
These medications have included heparin, warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin.
|
heparin
|
calcium channel antagonists
|
NONE
|
Abciximab_ddi.xml
|
DDI-DrugBank.d532.s2
|
DDI-DrugBank.d532.s2.p2
|
Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of EQUETROTM are the following: Acetazolamide, azole antifungals, cimetidine, clarithromycin(1), dalfopristin, danazol, delavirdine, diltiazem, erythromycin(1), fluoxetine, fluvoxamine, grapefruit juice, isoniazid, itraconazole, ketoconazole, loratadine, nefazodone, niacinamide, nicotinamide, protease inhibitors, propoxyphene, quinine, quinupristin, troleandomycin, valproate(1), verapamil, zileuton.
|
dalfopristin
|
nicotinamide
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s4
|
DDI-DrugBank.d94.s4.p132
|
No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (muscle relaxants, intravenous agents, and local anesthetic agents) were reported in clinical trials.
|
muscle relaxants
|
anesthetic agents
|
NONE
|
Desflurane_ddi.xml
|
DDI-DrugBank.d363.s0
|
DDI-DrugBank.d363.s0.p0
|
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
|
cyclosporine
|
carvedilol
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s10
|
DDI-DrugBank.d269.s10.p0
|
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;
|
quinidine
|
tacrolimus
|
NONE
|
Saquinavir_ddi.xml
|
DDI-DrugBank.d124.s26
|
DDI-DrugBank.d124.s26.p71
|
Antacids, Sucralfate, Metal Cations, Multivitamins Quinolones form chelates with alkaline earth and transition metal cations.
|
Sucralfate
|
Multivitamins
|
NONE
|
Grepafloxacin_ddi.xml
|
DDI-DrugBank.d78.s0
|
DDI-DrugBank.d78.s0.p3
|
This effect may be mediated by the ability of rifampin to induce microsomal enzymes and, thus, the catabolism of warfarin.
|
rifampin
|
warfarin
|
MECHANISM
|
1115445.xml
|
DDI-MedLine.d116.s5
|
DDI-MedLine.d116.s5.p0
|
Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.
|
progesterone
|
Accutane
|
EFFECT
|
Isotretinoin_ddi.xml
|
DDI-DrugBank.d163.s4
|
DDI-DrugBank.d163.s4.p4
|
Butalbital, acetaminophen and caffeine may enhance the effects of: other narcotic analgesics, alcohol, general anesthetics, tranquilizers such as chlordiazepoxide, sedative-hypnotics, or other CNS depressants, causing increased CNS depression.
|
Butalbital
|
alcohol
|
EFFECT
|
Butalbital_ddi.xml
|
DDI-DrugBank.d559.s1
|
DDI-DrugBank.d559.s1.p3
|
Drugs and other substances demonstrated to be CYP 3A inhibitors on the basis of clinical studies involving benzodiazepines metabolized similarly to alprazolam or on the basis of in vitro studies with alprazolam or other benzodiazepines (caution is recommended during coadministration with alprazolam): Available data from clinical studies of benzodiazepines other than alprazolam suggest a possible drug interaction with alprazolam for the following: diltiazem, isoniazid, macrolide antibiotics such as erythromycin and clarithromycin, and grapefruit juice.
|
macrolide antibiotics
|
clarithromycin
|
NONE
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s8
|
DDI-DrugBank.d131.s8.p76
|
- The action of sulphonylureas and insulin may be enhanced by Bezalip or Bezalip retard.
|
insulin
|
Bezalip retard
|
EFFECT
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s3
|
DDI-DrugBank.d291.s3.p4
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
Etonogestrel
|
antifungals
|
INT
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p12
|
Concomitant treatment with methylxanthines (aminophylline, theophylline), steroids, or diuretics may potentiate any hypokalemic effect of adrenergic agonists.
|
aminophylline
|
adrenergic agonists
|
EFFECT
|
Arformoterol_ddi.xml
|
DDI-DrugBank.d284.s3
|
DDI-DrugBank.d284.s3.p8
|
In addition, higher-than expected steady-state serum concentrations of tricyclic antidepressants have been observed when therapy is initiated in patients already taking cimetidine.
|
tricyclic antidepressants
|
cimetidine
|
MECHANISM
|
Nortriptyline_ddi.xml
|
DDI-DrugBank.d202.s2
|
DDI-DrugBank.d202.s2.p0
|
Patients receiving both indomethacin and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.
|
furosemide
|
furosemide
|
NONE
|
Furosemide_ddi.xml
|
DDI-DrugBank.d231.s17
|
DDI-DrugBank.d231.s17.p2
|
Patients receiving azathioprine and allopurinol concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.
|
azathioprine
|
allopurinol
|
ADVISE
|
Azathioprine_ddi.xml
|
DDI-DrugBank.d233.s1
|
DDI-DrugBank.d233.s1.p0
|
Etonogestrel may interact with the following medications: acetaminophen (Tylenol), antibiotics such as ampicillin and tetracycline, anticonvulsants (Dilantin, Phenobarbital, Tegretol, Trileptal, Topamax, Felbatol), antifungals (Gris-PEG, Nizoral, Sporanox), atorvastatin (Lipitor), clofibrate (Atromid-S), cyclosporine (Neoral, Sandimmune), HIV drugs classified as protease inhibitors (Agenerase, Crixivan, Fortovase, Invirase, Kaletra, Norvir, Viracept), morphine (Astramorph, Kadian, MS Contin), phenylbutazone, prednisolone (Prelone), rifadin (rifampin), St. Johns wort, temazepam, theophylline (Theo-Dur), and vitamin C.
|
anticonvulsants
|
Astramorph
|
NONE
|
Etonogestrel_ddi.xml
|
DDI-DrugBank.d484.s0
|
DDI-DrugBank.d484.s0.p275
|
Caution should be used when administering or taking TARCEVA with ketoconazole and other strong CYP3A4 inhibitors such as, but not limited to, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, troleandomycin (TAO), and voriconazole .
|
TARCEVA
|
TAO
|
ADVISE
|
Erlotinib_ddi.xml
|
DDI-DrugBank.d456.s1
|
DDI-DrugBank.d456.s1.p11
|
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride
|
VIRACEPT
|
terfenadine
|
ADVISE
|
Nelfinavir_ddi.xml
|
DDI-DrugBank.d340.s6
|
DDI-DrugBank.d340.s6.p5
|
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NIMBEX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistemethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.
|
aminoglycosides
|
quinidine
|
NONE
|
Cisatracurium Besylate_ddi.xml
|
DDI-DrugBank.d60.s12
|
DDI-DrugBank.d60.s12.p53
|
Medications can interfere with folate utilization, including: anticonvulsant medications (such as phenytoin, and primidone) metformin (sometimes prescribed to control blood sugar in type 2 diabetes) sulfasalazine (used to control inflammation associated with Crohns disease and ulcerative colitis) triamterene (a diuretic) Methotrexate There has been concern about the interaction between vitamin B12 and folic acid.
|
diuretic
|
Methotrexate
|
NONE
|
Folic Acid_ddi.xml
|
DDI-DrugBank.d425.s1
|
DDI-DrugBank.d425.s1.p39
|
Codeine in combination with other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, or other CNS depressants (including alcohol) has additive depressant effects.
|
Codeine
|
alcohol
|
EFFECT
|
Codeine_ddi.xml
|
DDI-DrugBank.d464.s0
|
DDI-DrugBank.d464.s0.p6
|
Interactions for vitamin D analogues (Vitamin D2, Vitamin D3, Calcitriol, and Calcidiol): Cholestyramine: Cholestyramine has been reported to reduce intestinal absorption of fat soluble vitamins;
|
vitamin D analogues
|
Vitamin D2
|
NONE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s0
|
DDI-DrugBank.d98.s0.p0
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
zafirlukast
|
TIKOSYN
|
ADVISE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p75
|
Drugs which induce CYP3A4 activity (eg, phenobarbital, rifampin, rifabutin) would be expected to increase the clearance of efavirenz resulting in lowered plasma concentrations.
|
phenobarbital
|
efavirenz
|
MECHANISM
|
Efavirenz_ddi.xml
|
DDI-DrugBank.d531.s5
|
DDI-DrugBank.d531.s5.p2
|
Thus, careful monitoring of clinical status is warranted when rifampin is administered or discontinued in haloperidol-treated patients.
|
rifampin
|
haloperidol
|
ADVISE
|
Haloperidol_ddi.xml
|
DDI-DrugBank.d186.s6
|
DDI-DrugBank.d186.s6.p0
|
Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with anagrelide in clinical trials were aspirin, acetaminophen, furosemide, iron, ranitidine, hydroxyurea, and allopurinol.
|
acetaminophen
|
hydroxyurea
|
NONE
|
Anagrelide_ddi.xml
|
DDI-DrugBank.d75.s2
|
DDI-DrugBank.d75.s2.p16
|
The benzodiazepines, including alprazolam, produce additive CNS depressant effects when co-administered with other psychotropic medications, anticonvulsants, antihistaminics, ethanol, and other drugs which themselves produce CNS depression.
|
benzodiazepines
|
psychotropic medications
|
EFFECT
|
Alprazolam_ddi.xml
|
DDI-DrugBank.d131.s0
|
DDI-DrugBank.d131.s0.p1
|
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.
|
thiazides
|
sympathomimetics
|
NONE
|
Chlorpropamide_ddi.xml
|
DDI-DrugBank.d245.s4
|
DDI-DrugBank.d245.s4.p7
|
Acellular, live and live-attenuated vaccines should not be administered during RAPTIVA treatment.
|
live-attenuated vaccines
|
RAPTIVA
|
ADVISE
|
Efalizumab_ddi.xml
|
DDI-DrugBank.d44.s2
|
DDI-DrugBank.d44.s2.p5
|
Probenecid: Concomitant administration of TORADOL ORAL and probenecid resulted in decreased clearance of ketorolac and significant increases in ketorolac plasma levels (total AUC increased approximately threefold from 5.4 to 17.8 m g/h/mL) and terminal half-life increased approximately twofold from 6.6 to 15.1 hours.
|
Probenecid
|
ketorolac
|
NONE
|
Ketorolac_ddi.xml
|
DDI-DrugBank.d3.s9
|
DDI-DrugBank.d3.s9.p3
|
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.
|
loop diuretics
|
thiazide diuretics
|
NONE
|
Hydrochlorothiazide_ddi.xml
|
DDI-DrugBank.d162.s12
|
DDI-DrugBank.d162.s12.p8
|
Monoamine oxidase (MAO) inhibitors such as isocarboxazid (e.g., Marplan), phenelzine (e.g., Nardil), procarbazine (e.g., Matulane), selegiline (e.g., Eldepryl), and tranylcypromine (e.g., Parnate): Using these medicines with L-tryptophan may increase the chance of side effects.
|
procarbazine
|
Eldepryl
|
NONE
|
L-Tryptophan_ddi.xml
|
DDI-DrugBank.d63.s0
|
DDI-DrugBank.d63.s0.p47
|
Digitalis: Vitamin D dosage must be determined with care in patients undergoing treatment with digitalis, as hypercalcemia in such patients may precipitate cardiac arrhythmias.
|
Vitamin D
|
digitalis
|
ADVISE
|
Calcidiol_ddi.xml
|
DDI-DrugBank.d98.s7
|
DDI-DrugBank.d98.s7.p2
|
Clinical trials have indicated that Pulmozyme can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral antibiotics, bronchodilators, enzyme supplements, vitamins, oral or inhaled corticosteroids, and analgesics.
|
Pulmozyme
|
corticosteroids
|
NONE
|
Dornase Alfa_ddi.xml
|
DDI-DrugBank.d93.s0
|
DDI-DrugBank.d93.s0.p3
|
Concurrent administration of etanercept (another TNF -blocking agent) and anakinra (an interleukin-1 antagonist) has been associated with an increased risk of serious infections, and increased risk of neutropenia and no additional benefit compared to these medicinal products alone.
|
etanercept
|
anakinra
|
EFFECT
|
Infliximab_ddi.xml
|
DDI-DrugBank.d45.s0
|
DDI-DrugBank.d45.s0.p0
|
The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of phenytoin and other drugs had not changed.
|
fluvoxamine
|
phenytoin
|
NONE
|
11206048.xml
|
DDI-MedLine.d60.s2
|
DDI-MedLine.d60.s2.p3
|
Therefore, co-administration of bupropion with drugs that are metabolized by CYP2D6 isoenzyme including certain antidepressants (e.g., nortriptyline, imipramine, desipramine, paroxetine, fluoxetine, sertraline), antipsychotics (e.g., haloperidol, risperidone, thioridazine), beta-blockers (e.g., metoprolol), and Type 1C antiarrhythmics (e.g., propafenone, flecainide), should be approached with caution and should be initiated at the lower end of the dose range of the concomitant medication.
|
paroxetine
|
metoprolol
|
NONE
|
Bupropion_ddi.xml
|
DDI-DrugBank.d5.s17
|
DDI-DrugBank.d5.s17.p77
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
haloperidol
|
primidone
|
NONE
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p243
|
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
|
glucocorticoids
|
EGF
|
EFFECT
|
3881461.xml
|
DDI-MedLine.d12.s7
|
DDI-MedLine.d12.s7.p11
|
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines, and can be used to treat amphetamine poisoning.
|
Chlorpromazine
|
amphetamines
|
EFFECT
|
Dextroamphetamine_ddi.xml
|
DDI-DrugBank.d236.s16
|
DDI-DrugBank.d236.s16.p3
|
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.
|
cerivastatin
|
erythromycin
|
MECHANISM
|
Cerivastatin_ddi.xml
|
DDI-DrugBank.d141.s12
|
DDI-DrugBank.d141.s12.p2
|
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.
|
indomethacin
|
PROLEUKIN
|
EFFECT
|
Aldesleukin_ddi.xml
|
DDI-DrugBank.d114.s2
|
DDI-DrugBank.d114.s2.p10
|
In vitro studies have shown that the metabolism of docetaxel may be modified by the concomitant administration of compounds that induce, inhibit, or are metabolized by cytochrome P450 3A4, such as cyclosporine, terfenadine, ketoconazole, erythromycin, and troleandomycin.
|
docetaxel
|
cyclosporine
|
MECHANISM
|
Docetaxel_ddi.xml
|
DDI-DrugBank.d371.s1
|
DDI-DrugBank.d371.s1.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
warfarin sodium
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p22
|
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.
|
MAO-inhibitors
|
Bezalip
|
ADVISE
|
Bezafibrate_ddi.xml
|
DDI-DrugBank.d291.s11
|
DDI-DrugBank.d291.s11.p3
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
adrenocortical steroids
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p0
|
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and epinephrine may occur.
|
BETAGAN
|
epinephrine
|
EFFECT
|
Levobunolol_ddi.xml
|
DDI-DrugBank.d252.s0
|
DDI-DrugBank.d252.s0.p2
|
Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.
|
tetracyclines
|
contraceptives
|
EFFECT
|
Demeclocycline_ddi.xml
|
DDI-DrugBank.d409.s2
|
DDI-DrugBank.d409.s2.p0
|
Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrom-bin time response, in man significantly include: adrenocortical steroids;alcohol*;antacids;antihistamines;barbiturates;carbamazepine;chloral hydrate*;chlordiazepoxide;cholestyramine;diet high in vitamin K;diuretics*;ethchlorvynol;glutethimide;griseofulvin;haloperidol;meprobamate;oral contraceptives;paraldehyde;primidone;ranitidine*;rifampin;unreliable prothrombin time determinations;vitamin C;warfarin sodium under-dosage.
|
anticoagulant
|
ethchlorvynol
|
EFFECT
|
Anisindione_ddi.xml
|
DDI-DrugBank.d64.s29
|
DDI-DrugBank.d64.s29.p11
|
Agents that have been found, or are expected to have decreased plasma levels in the presence of EQUETROTM due to induction of CYP enzymes are the following: Acetaminophen, alprazolam, amitriptyline, bupropion, buspirone, citalopram, clobazam, clonazepam, clozapine, cyclosporin, delavirdine, desipramine, diazepam, dicumarol, doxycycline, ethosuximide, felbamate, felodipine, glucocorticoids, haloperidol, itraconazole, lamotrigine, levothyroxine, lorazepam, methadone, midazolam, mirtazapine, nortriptyline, olanzapine, oral contraceptives(3), oxcarbazepine, Phenytoin(4), praziquantel, protease inhibitors, quetiapine, risperidone, theophylline, topiramate, tiagabine, tramadol, triazolam, valproate, warfarin(5) , ziprasidone, and zonisamide.
|
levothyroxine
|
warfarin
|
NONE
|
Carbamazepine_ddi.xml
|
DDI-DrugBank.d94.s11
|
DDI-DrugBank.d94.s11.p801
|
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.
|
Mefloquine
|
beta-adrenergic blocking agents
|
EFFECT
|
Mefloquine_ddi.xml
|
DDI-DrugBank.d220.s9
|
DDI-DrugBank.d220.s9.p1
|
Coadministration of almotriptan and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.
|
almotriptan
|
ketoconazole
|
MECHANISM
|
Almotriptan_ddi.xml
|
DDI-DrugBank.d299.s10
|
DDI-DrugBank.d299.s10.p0
|
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.
|
clarithromycin
|
cisapride
|
MECHANISM
|
Cisapride_ddi.xml
|
DDI-DrugBank.d237.s2
|
DDI-DrugBank.d237.s2.p7
|
Studies have shown that lansoprazole does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as warfarin, antipyrine, indomethacin, ibuprofen, phenytoin, propranolol, prednisone, diazepam, clarithromycin, or terfenadine in healthy subjects.
|
propranolol
|
terfenadine
|
NONE
|
Lansoprazole_ddi.xml
|
DDI-DrugBank.d431.s1
|
DDI-DrugBank.d431.s1.p48
|
Inhibitors of this isoenzyme (e.g., macrolide antibiotics, azole antifungal agents, protease inhibitors, serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, grapefruit juice, nefazadone, norfloxacin, quinine, zafirlukast) should be cautiously coadministered with TIKOSYN as they can potentially increase dofetilide levels.
|
azole antifungal agents
|
diltiazem
|
NONE
|
Dofetilide_ddi.xml
|
DDI-DrugBank.d558.s25
|
DDI-DrugBank.d558.s25.p16
|
Sumatriptan and D.H.E. 45 (dihydroergotamine mesylate) Injection, USP should not be taken within 24 hours of each other..
|
Sumatriptan
|
D.H.E. 45
|
ADVISE
|
Dihydroergotamine_ddi.xml
|
DDI-DrugBank.d410.s2
|
DDI-DrugBank.d410.s2.p0
|
Concomitant use of SPRYCEL and drugs that inhibit CYP3A4 (eg, ketoconazole, itraconazole, erythromycin, clarithromycin, ritonavir, atazanavir, indinavir, nefazodone, nelfinavir, saquinavir, telithromycin) may increase exposure to dasatinib and should be avoided.
|
SPRYCEL
|
nelfinavir
|
MECHANISM
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s1
|
DDI-DrugBank.d48.s1.p8
|
H2 Blockers/Proton Pump Inhibitors: Long-term suppression of gastric acid secretion by H2 blockers or proton pump inhibitors (eg, famotidine and omeprazole) is likely to reduce dasatinib exposure.
|
H2 blockers
|
dasatinib
|
EFFECT
|
Dasatinib_ddi.xml
|
DDI-DrugBank.d48.s11
|
DDI-DrugBank.d48.s11.p14
|
ketoconazole), macrolide antibiotics (e.g. erythromycin), and HIV protease inhibitors (e.g. ritonavir, indinavir and saquinavir) should have their dose of SUBUTEX or SUBOXONE adjusted.
|
indinavir
|
SUBUTEX
|
NONE
|
Buprenorphine_ddi.xml
|
DDI-DrugBank.d380.s2
|
DDI-DrugBank.d380.s2.p31
|
Due to wide interindividual variability in the dose adjustment required, it is recommended that cyclosporine concentrations be monitored closely after initiation of carvedilol therapy and that the dose of cyclosporine be adjusted as appropriate.
|
carvedilol
|
cyclosporine
|
ADVISE
|
Carvedilol_ddi.xml
|
DDI-DrugBank.d269.s10
|
DDI-DrugBank.d269.s10.p2
|
Both the magnitude and duration of central nervous system and cardiovascular effects may be enhanced when ALFENTA is administered in combination with other CNS depressants such as barbiturates, tranquilizers, opioids, or inhalation general anesthetics.
|
ALFENTA
|
barbiturates
|
EFFECT
|
Alfentanil_ddi.xml
|
DDI-DrugBank.d8.s0
|
DDI-DrugBank.d8.s0.p1
|
Monitoring for amiodarone toxicity and serial measurement of amiodarone serum concentration during concomitant protease inhibitor therapy should be considered.
|
amiodarone
|
protease inhibitor
|
NONE
|
Amiodarone_ddi.xml
|
DDI-DrugBank.d143.s13
|
DDI-DrugBank.d143.s13.p1
|
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.
|
Lorazepam
|
barbiturates
|
EFFECT
|
Lorazepam_ddi.xml
|
DDI-DrugBank.d18.s1
|
DDI-DrugBank.d18.s1.p3
|
In vitro displacement studies with highly protein-bound drugs such as furosemide, propranolol, captopril, nicardipine, pravastatin, glyburide, warfarin, phenytoin, acetylsalicylic acid, tolbutamide, and metformin showed no influence on the extent of nateglinide protein binding.
|
captopril
|
pravastatin
|
NONE
|
Nateglinide_ddi.xml
|
DDI-DrugBank.d460.s11
|
DDI-DrugBank.d460.s11.p22
|
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.
|
benzodiazepines
|
phenothiazines
|
EFFECT
|
Estazolam_ddi.xml
|
DDI-DrugBank.d338.s1
|
DDI-DrugBank.d338.s1.p6
|
Binding to Serum Proteins: The following agents may either inhibit levothyroxine sodium binding to serum proteins or alter the concentrations of serum binding proteins: androgens and related anabolic hormones, asparaginase, clofibrate, estrogens and estrogen-containing compounds, 5-fluorouracil, furosemide, glucocorticoids, meclofenamic acid, mefenamic acid, methadone, perphenazine, phenylbutazone, phenytoin, salicylates, tamoxifen.
|
levothyroxine sodium
|
phenylbutazone
|
MECHANISM
|
Levothyroxine_ddi.xml
|
DDI-DrugBank.d411.s3
|
DDI-DrugBank.d411.s3.p13
|
Haloperidol: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.
|
Haloperidol
|
amphetamines
|
EFFECT
|
Lisdexamfetamine_ddi.xml
|
DDI-DrugBank.d158.s14
|
DDI-DrugBank.d158.s14.p2
|
In patients receiving another serotonin reuptake inhibitor drug in combination with monoamine oxidase inhibitors (MAOI), there have been reports of serious, sometimes fatal, reactions including hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, and mental status changes that include extreme agitation progressing to delirium and coma.
|
serotonin reuptake inhibitor drug
|
MAOI
|
EFFECT
|
Fluvoxamine_ddi.xml
|
DDI-DrugBank.d76.s1
|
DDI-DrugBank.d76.s1.p1
|
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.
|
IOPIDINE
|
opiates
|
ADVISE
|
Apraclonidine_ddi.xml
|
DDI-DrugBank.d224.s1
|
DDI-DrugBank.d224.s1.p3
|
A two-way interaction between the hydantoin antiepileptic, phenytoin, and the coumarin anticoagulants has been suggested.
|
hydantoin antiepileptic
|
coumarin anticoagulant
|
INT
|
Ethotoin_ddi.xml
|
DDI-DrugBank.d359.s2
|
DDI-DrugBank.d359.s2.p1
|
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.
|
decamethonium
|
Coly-Mycin M
|
EFFECT
|
Colistimethate_ddi.xml
|
DDI-DrugBank.d250.s2
|
DDI-DrugBank.d250.s2.p19
|
Geocillin (carbenicillin indanyl sodium) blood levels may be increased and prolonged by concurrent administration of probenecid.
|
Geocillin
|
carbenicillin indanyl sodium
|
NONE
|
Carbenicillin_ddi.xml
|
DDI-DrugBank.d545.s0
|
DDI-DrugBank.d545.s0.p0
|
There is one report suggesting that the concomitant use of trazodone hydrochloride (Desyrel) and buspirone HCl may have caused 3- to 6-fold elevations on SGPT (ALT) in a few patients.
|
trazodone hydrochloride
|
buspirone HCl
|
EFFECT
|
Buspirone_ddi.xml
|
DDI-DrugBank.d463.s1
|
DDI-DrugBank.d463.s1.p1
|
In vitro studies have shown CASODEX can displace coumarin anticoagulants, such as warfarin, from their protein-binding sites.
|
CASODEX
|
coumarin anticoagulant
|
MECHANISM
|
Bicalutamide_ddi.xml
|
DDI-DrugBank.d266.s0
|
DDI-DrugBank.d266.s0.p0
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.